Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia

od Laverdière, Isabelle, Boileau, Meaghan, Neumann, Andrea L., Frison, Héloïse, Mitchell, Amanda, Ng, Stanley W. K., Wang, Jean C. Y., Minden, Mark D., Eppert, Kolja
Wydane w Blood Cancer J (2018)

Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation

od Da Costa, Elodie M., Armaos, Gregory, McInnes, Gabrielle, Beaudry, Annie, Moquin-Beaudry, Gaël, Bertrand-Lehouillier, Virginie, Caron, Maxime, Richer, Chantal, St-Onge, Pascal, Johnson, Jeffrey R., Krogan, Nevan, Sai, Yuka, Downey, Michael, Rafei, Moutih, Boileau, Meaghan, Eppert, Kolja, Flores-Díaz, Ema, Haman, André, Hoang, Trang, Sinnett, Daniel, Beauséjour, Christian, McGraw, Serge, Raynal, Noël J.-M.
Wydane w J Exp Clin Cancer Res (2019)

Mutant H3 histones drive human pre-leukemic hematopoietic stem cell expansion and promote leukemic aggressiveness

od Boileau, Meaghan, Shirinian, Margret, Gayden, Tenzin, Harutyunyan, Ashot S., Chen, Carol C. L., Mikael, Leonie G., Duncan, Heather M., Neumann, Andrea L., Arreba-Tutusaus, Patricia, De Jay, Nicolas, Zeinieh, Michele, Rossokhata, Katya, Zhang, Yelu, Nikbakht, Hamid, Mouawad, Carine, Massoud, Radwan, Frey, Felice, Nasr, Rihab, El Cheikh, Jean, El Sabban, Marwan, Kleinman, Claudia L., Mahfouz, Rami, Minden, Mark D., Jabado, Nada, Bazarbachi, Ali, Eppert, Kolja
Wydane w Nat Commun (2019)